NCT03181100View on ClinicalTrials.gov

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 27, 2017

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Metastatic Thyroid Gland CarcinomaPoorly Differentiated Thyroid Gland CarcinomaStage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8Thyroid Gland Anaplastic CarcinomaUnresectable Thyroid Gland Carcinoma
Interventions
DRUG

Atezolizumab

Given IV

BIOLOGICAL

Bevacizumab

Given IV

DRUG

Cobimetinib

Given PO

DRUG

Nab-paclitaxel

Given IV

DRUG

Paclitaxel

Given IV

DRUG

Vemurafenib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER